These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12945474)

  • 21. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.
    Coodley GO; Jorgensen M; Kirschenbaum J; Sparks C; Zeigler L; Albertson BD
    Am J Med; 2008 Jul; 121(7):604-10. PubMed ID: 18538295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
    Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient characteristics and medical care costs associated with hypertriglyceridemia.
    Nichols GA; Arondekar B; Garrison LP
    Am J Cardiol; 2011 Jan; 107(2):225-9. PubMed ID: 21211599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study].
    Forti N; Ramires JA
    Arq Bras Cardiol; 1991 Sep; 57(3):253-61. PubMed ID: 1824203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A survey on the status of lipid-lowering therapy in 180 hypercholesterolemic patients].
    Cai S; Xia S; Xie H; Yao X; Wang L
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Oct; 23(5):378-81; discussion 381-2. PubMed ID: 12482372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.
    Waters DD; Brotons C; Chiang CW; Ferrières J; Foody J; Jukema JW; Santos RD; Verdejo J; Messig M; McPherson R; Seung KB; Tarasenko L;
    Circulation; 2009 Jul; 120(1):28-34. PubMed ID: 19546386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.
    Lu CY; Law MR; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
    Clin Ther; 2011 Jan; 33(1):135-44. PubMed ID: 21397779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetics and secondary prevention patients: the role of education and knowledge].
    Yiğiner O; Ozmen N; Ozçelik F; Inanç T; Kardeşoğlu E; Uz O; Işılak Z; Aparcı M; Sahin I; Arslan E; Cebeci BS
    Turk Kardiyol Dern Ars; 2010 Dec; 38(8):544-50. PubMed ID: 21248454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in sweden.
    Hambraeus K; Lindhagen L; Tydén P; Lindahl B; Lagerqvist B
    Am J Cardiol; 2014 Jan; 113(1):17-22. PubMed ID: 24169006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost of care for patients treated with lipid-lowering drugs.
    Carlsson A; Borgström F; Stålhammar J; Alemao E; Yin D; Jönsson L
    Pharmacoeconomics; 2004; 22 Suppl 3():25-35. PubMed ID: 15669151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy.
    Di Martino M; Degli Esposti L; Ruffo P; Bustacchini S; Catte A; Sturani A; Degli Esposti E
    Eur J Clin Pharmacol; 2005 May; 61(3):225-30. PubMed ID: 15824910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
    Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How drug prices are set: an example from the perspective of a social security association.
    Eichler HG; Bucsics A; Wieninger P
    Clin Pharmacol Ther; 2002 Jul; 72(1):101-3. PubMed ID: 12152009
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevention of cardiovascular disease: plea for a rationale use of diet and lipid-lowering drugs.
    Scheen AJ
    Acta Clin Belg; 2003; 58(3):149-51. PubMed ID: 12945473
    [No Abstract]   [Full Text] [Related]  

  • 39. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 40. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.